Table of Contents Author Guidelines Submit a Manuscript
International Journal of Rheumatology
Volume 2017 (2017), Article ID 3076017, 6 pages
https://doi.org/10.1155/2017/3076017
Research Article

Isolated Ro52 Antibodies as Immunological Marker of a Mild Phenotype of Undifferentiated Connective Tissue Diseases

1Biochemistry Unit, Central Laboratory, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain
2Immunology Unit, Central Laboratory, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain
3Rheumatology Department, Complejo Hospitalario Universitario de Canarias, Tenerife, Spain

Correspondence should be addressed to Yvelise Barrios; moc.liamg@soirrab.esilevy

Received 11 November 2016; Accepted 29 December 2016; Published 22 January 2017

Academic Editor: Charles J. Malemud

Copyright © 2017 Ana Alonso-Larruga et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The term undifferentiated connective tissue disease (UCTD) is used to describe undiagnosed patients that do not fulfill classification criteria for definite connective tissue disease (Systemic Lupus, Systemic Sclerosis, Sjögren Syndrome, and Dermatomyositis/Polymyositis). It is important to find serological markers as predictors of the evolution or severity of these diseases. The objective of this retrospective study was to investigate if there was a milder subgroup of UCTD with a special clinical profile consisting only in the presence of anti-Ro52 autoantibodies. Immunological and clinical records of 62 patients attending the hospital during 30 months were studied. Results showed a target population formed by mostly women, aged between 40 and 80 years at the moment of the study, with a registered age of onset between 40 and 60 years. Speckled pattern was the most frequent pattern found by indirect immunofluorescence. Given the obtained results and keeping in mind possible limitations because of sample size, isolated positive anti-Ro52 autoantibodies seem to lead to a benign effect in terms of evolution of the disease. As a future objective, the follow-up of these patients should be necessary to investigate new clinical symptoms, serological markers, or development of a definite connective tissue disease over time.